

Return on Innovation



Global health R&D delivers for Illinois



US government (USG) investment in global health R&D has delivered

\$60.9 million
to Illinois research institutions*

850+ new jobs
for Illinois†

Illinois's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
Northwestern University	\$24.0 million
University of Illinois at Chicago	\$15.3 million
University of Illinois at Urbana-Champaign	\$7.4 million
University of Chicago	\$4.8 million
Loyola University of Chicago	\$4.2 million
Rosalind Franklin University of Medicine and Science	\$2.6 million
Rush University Medical Center	\$2.5 million

Neglected diseases in Illinois‡

HIV diagnoses	14,714
Tuberculosis cases	3,292
West Nile cases	749
Malaria cases	445
Dengue cases	149

Illinois industry in global health R&D


AbbVie: North Chicago, Mettawa
Astellas: Northbrook
Lavax: Palatine
Luminex: Northbrook
Takeda Pharmaceuticals USA: Deerfield

Global health R&D at work in the Prairie State



Researchers at the University of Illinois College of Medicine at Rockford are conducting clinical trials of a vaccine candidate against lymphatic filariasis (LF), one of the world's most profoundly disfiguring diseases. Commonly known as elephantiasis, LF is transmitted by mosquitoes carrying parasitic worms. Currently, at least 36 million people worldwide are living with the severe pain, disability, and stigma of the disease; and 856 million people are at risk.

Illinois's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡



89¢ of every dollar

the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, West Nile virus disease cases 2008-2016, Malaria cases 2008-2014, Dengue virus infection cases 2010-2016.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.